TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased
to announce that it is exhibiting at the EuroEcho- Imaging 2017 Conference in Lisbon, Portugal, December 6 – 8, 2017. The
Conference is the world’s largest cardiovascular imaging congress. It attracted over 3,200 attendees from 90 countries last
year and is the place to meet with world-renowned global experts in the field of cardiovascular imaging.
“The sales and marketing team is excited about introducing the new 4-chamber VMS heart analysis system to the
leading cardiologists for the first time,” stated Dr. George Adams, CEO of Ventripoint. “This Conference has always been an
excellent way to engage customers and learn about their plans for expansion and upgrading their echocardiography services.”
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed
countries. VMS is the first cost-effective and accurate tool for measuring heart function. The Company has developed a suite of
applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure
and normal hearts.
For further information please contact:
Dr. George Adams,
President & CEO
Telephone: (519) 803-6937
email: gadams@ventripoint.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which
address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s
exercise of business judgment as well as assumptions made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These
statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise
publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to
reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable
assumptions, no assurance can be given that these expectations will materialize.
